Details of the Drug Reposition

General Information of This Drug (ID: DM5BV5H)

• Drug Name: Daxdilimab (DM5BV5H)
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lupus nephritis	DISCVGPZ	4A40.0Y	Phase 2	[1]
Dermatomyositis	DIS50C5O	4A41.0	Phase 2	[2]
Discoid lupus erythematosus	DISMK3AH	EB51.0	Phase 2	[3]
Alopecia areata	DIS0XXBJ	ED70.2	Phase 2	[4]

References

• [1] ClinicalTrials.gov (NCT05540665) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05669014) A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05591222) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus. U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05368103) A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata. U.S.National Institutes of Health.